New Drugs for Osteoporosis: Comparison of the Costs and Required Returns With Those of Other Drugs Intended for Long-Term Use

Author： Edwards M.

Publisher： Adis International

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.15, Iss.3, 1999-03, pp. : 269-278

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Use of behavioural and long-term potentiation models in the development of memory-improving drugs

By Blokland Arjan Boess Frank

Expert Opinion on Drug Discovery, Vol. 3, Iss. 9, 2008-09 ,pp. : 1067-1080

Informa Healthcare

Access to resources Recommend Favorite

Non-investigational antiarrhythmic drugs: long-term use and limitations

By Gjesdal Knut

Expert Opinion on Drug Safety, Vol. 8, Iss. 3, 2009-05 ,pp. : 345-355

Informa Healthcare

Access to resources Recommend Favorite

Long-term use of antiplatelet drugs by patients with transient ischaemic attack

By Østergaard Kamilla Madsen Charlotte Liu Marie-Louise Bak Søren Hallas Jesper Gaist David

European Journal of Clinical Pharmacology, Vol. 70, Iss. 2, 2014-02 ,pp. : 241-248

Springer Publishing Company

Access to resources Recommend Favorite

New findings with old drugs for osteoporosis

By Doggrell Sheila A

Expert Opinion on Pharmacotherapy, Vol. 10, Iss. 3, 2009-02 ,pp. : 513-516

Informa Healthcare

Access to resources Recommend Favorite

Statins: new drugs for treating osteoporosis?

By Whitfield J.F.

Expert Opinion on Investigational Drugs, Vol. 10, Iss. 3, 2001-03 ,pp. : 417-417

Informa Healthcare

Access to resources Recommend Favorite